Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Given its regenerative properties and favorable safety profile, AOD9604 holds promise as a novel therapeutic agent for OA, especially when used in conjunction with established treatments like HA [1]
:max_bytes(150000):strip_icc()/VWH-GettyImages-2218717437-6a4c5c84bdfd46feb41334a30334464d.jpg)
AOD-9604 vs GLP-1 Medications GLP-1 medications such as Semaglutide, Tirzepatide, and Retatrutide primarily work through: Appetite suppression Blood sugar regulation Delayed gastric emptying AOD-9604 works differently
The diagnostic process has been aided by the development of the SPEC-FPL and PSL tests, which stand for Specific Feline Pancreatic Lipase and Pancreatic Sensitive Lipase, respectively
Membership does not include or guarantee a prescription
Yes (strong) FDA status FDA-approved (T2D and obesity) Compound NAD+ (intravenous or subcutaneous) Mechanism Direct NAD+ supplementation Route IV infusion or subcutaneous Acts on appetite
US$ 21.03
US$ 27.01
US$ 24.43
US$ 21.55
US$ 21.95
US$ 25.51
![Gabelzinken FEM 3A - 800 bis 2.400 x 100 x 45 mm Länge [mm]:2.200](https://cdn.shopify.com/s/files/1/0883/1290/6051/files/GabelzinkeSO.png?v=1756818691)
